Your browser doesn't support javascript.
loading
Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency.
Karbiener, Michael; Kindle, Gerhard; Meyts, Isabelle; Seppänen, Mikko R J; Candotti, Fabio; Kamieniak, Marta; Ilk, Reinhard; Kreil, Thomas R; Seidel, Markus G.
Afiliación
  • Karbiener M; Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.
  • Kindle G; Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Meyts I; Centre for Biobanking FREEZE, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Seppänen MRJ; Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Candotti F; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • Kamieniak M; Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
  • Ilk R; ERN-RITA Core Center, RITAFIN, Helsinki, Finland.
  • Kreil TR; Rare Disease Center and Pediatric Research Center, Children and Adolescents, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
  • Seidel MG; Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
J Med Virol ; 96(6): e29738, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38884390
ABSTRACT
Immunocompromised individuals are at significantly elevated risk for severe courses of coronavirus disease 2019 (COVID-19). In addition to vaccinationsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies (nAbs) have been applied throughout the pandemic, with time of treatment onset and potency against the currently prevailing virus variant identified as relevant factors for medical benefit. Using data from the European Society for Immunodeficiencies (ESID) registry, the present study evaluated COVID-19 cases in three groups of patients with inborn errors of immunity (IEI; 981 agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT); 8960 non-agammaglobulinemia patients on IGRT; 14 428 patients without IGRT), and the neutralizing capacity of 1100 immunoglobulin lots against SARS-CoV-2 ("Wuhan" and Omicron strains), throughout 3 years. From the first (2020/2021) to the second (2021/2022) cold season, i.e., during the virus drift to the more contagious Omicron variants, an increase in case numbers was recorded that was comparable (~2- to 3-fold) for all three study groups. During the same period, immunoglobulin lots showed a profound nAb increase against the archetypal SARS-CoV-2 strain, yet only low levels of Omicron nAbs. Notably, shortly before the third (2022/2023) cold season, Omicron-neutralizing capacity of released immunoglobulin lots had plateaued at high levels. From the second to the third cold season, COVID-19 cases dropped markedly. While a ~6-fold case reduction was recorded for the groups of non-agammaglobulinemia patients on IGRT and IEI patients not receiving IGRT, the decline was ~30-fold for the group of agammaglobulinemia patients on IGRT. These findings suggest a substantial COVID-19-protective effect of IGRT, at least for distinct groups of antibody-deficient patients.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Agammaglobulinemia / Anticuerpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Idioma: En Revista: J Med Virol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Agammaglobulinemia / Anticuerpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Idioma: En Revista: J Med Virol Año: 2024 Tipo del documento: Article